A population-level evaluation of the effect of antiretroviral therapy on cancer incidence in Kyadondo County, Uganda, 1999-2008

Journal of Acquired Immune Deficiency Syndromes

Volumn 69, Issue 4, 2015, Pages 481-486

  Mutyaba, Innocent ^a,b   Phipps, Warren ^c,d   Krantz, Elizabeth M ^d   Goldman, Jason D ^c   Nambooze, Sarah ^e   Orem, Jackson ^a,b   Wabinga, Henry R ^b,e   Casper, Corey ^c,d  

^a UGANDA CANCER INSTITUTE   (Uganda)

^b MAKERERE UNIVERSITY COLLEGE OF HEALTH SCIENCES   (Uganda)

^c UNIVERSITY OF WASHINGTON   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

^e Kampala Cancer Registry   (Uganda)

Author keywords

Antiretroviral therapy; Cancer in Africa; Cancer incidence; HIV AIDS; Uganda

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CHILD; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; KAPOSI SARCOMA; LIVER CANCER; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; NEOPLASM; NEWBORN; NONHODGKIN LYMPHOMA; POPULATION RESEARCH; PRIORITY JOURNAL; PROSTATE CANCER; STOMACH CANCER; UGANDA; HIV INFECTIONS; INCIDENCE; MIDDLE AGED; NEOPLASMS; PRESCHOOL CHILD; RISK FACTOR; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-HIV AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; HIV INFECTIONS; HUMANS; INCIDENCE; INFANT; MALE; MIDDLE AGED; NEOPLASMS; RISK FACTORS; UGANDA; YOUNG ADULT;

EID: 84975322158     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000620     Document Type: Article

References (36)

1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893-2917.
2. Parkin DM, Sitas F, Chirenje M, et al. Part I: cancer in indigenous africans-burden, distribution, and trends. Lancet Oncol. 2008;9: 683-692.
3. Mbulaiteye SM, Katabira ET, wabinga H, et al. Spectrum of cancers among HIV-infected persons in Africa: the uganda AIDS-cancer registry match study. Int J Cancer. 2006;118:985-990.
4. Coghill AE, Newcomb PA, Madeleine MM, et al. Contribution of HIV infection to mortality among cancer patients in uganda. AIDS. 2013;27: 2933-42.
5. Casper C. The increasing burden of HIV-associated malignancies in resource-limited regions. Annu Rev Med. 2011;62:157-170.
6. wabinga H, Parkin DM, Sitas F, et al. Cancer in Kampala, Uganda, in 1989-91: changes in the incidence in the era of AIDS. Int J Cancer. 1993;54:26-36.
7. wabinga HR, Parkin DM, wabwire-Mangen F, et al. Trends in cancer incidence in Kyadondo County, Uganda, 1960-1997. Br J Cancer. 2000; 82:1585-1592.
8. Parkin DM, Nabooze S, wabwire-Magen F, et al. Changing cancer incidence in Kampala, Uganda, 1991-2006. Int J Cancer. 2010;126:1187-1197.
9. Bedimo RJ, McGinnis KA, Dunlap M, et al. Incidence of non-AIDS-defining malignancies in HIV-infected versus noninfected patients in the HAART era: impact of immunosuppression. J Acquir Immune Defic Syndr. 2009;52:203-208.
10. Calabresi A, Ferraresi A, Festa A, et al. Incidence of AIDS-defining cancers and virus-related and non-virus-related non-AIDS-defining cancers among HIV-infected patients compared with the general population in a large health district of northern Italy, 1999-2009. HIV Med. 2013;14:481-490.
11. Patel P, Hanson DL, Sullivan PS, et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med. 2008;148:728-736.
12. Engels EA, Pfeiffer RM, Goedert JJ, et al. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS. 2006;20:1645-1654.
13. Franceschi S, Lise M, Clifford GM, et al. Changing patterns of cancer incidence in the early- and late-HAART periods: the swiss HIV cohort study. Br J Cancer. 2010;103:416-422.
14. Polesel J, Franceschi S, Suligoi B, et al. Cancer incidence in people with AIDS in Italy. Int J Cancer. 2010;127:1437-1445.
15. Grulich AE, van Leeuwen MT, Falster MO, et al. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. 2007;370:59-67.
16. Eltom MA, Jemal A, Mbulaiteye SM, et al. Trends in kaposi's sarcoma and non-hodgkin's lymphoma incidence in the United States from 1973 through 1998. J Natl Cancer Inst. 2002;94:1204-1210.
17. Kaplan JE, Hanson D, Dworkin MS, et al. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis. 2000;30(suppl 1):S5-S14.
18. Lohse N, Hansen AB, Pedersen G, et al. Survival of persons with and without HIV infection in denmark, 1995-2005. Ann Intern Med. 2007; 146:87-95.
19. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators. N Engl J Med. 1998;338: 853-860.
20. Progress on Global Access to HIV Antiretroviral Therapy: A Report on "3 by 5" and beyond, March 2006. world Health Organization. Available at: http://www.who.int/hiv/fullreport-en-highres.pdf. Accessed December 20, 2010.
21. Towards Universal Access: Scaling Up Priority HIV/AIDS Interventions in the Health Sector: Progress Report 2007. wHO and UNICEF. Available at: http://www.who.int/hiv/mediacentre/universal-access- progress-report-en.pdf. Accessed December 20, 2010.
22. Towards Universal Access: Scaling up Priority HIV/AIDS Interventions in the Health Sector: Progress Report 2008. wHO, UNAIDS, and UNICEF. Available at: http://whqlibdoc.who.int/publications/2008/ 9789241596886-eng.pdf. Accessed December 20, 2010.
23. Towards Universal Access: Scaling up Priority HIV/AIDS Interventions in the Health Sector: Progress Report 2009. wHO, UNAIDS, and UNICEF. Available at: http://whqlibdoc.who.int/publications/2009/ 9789241598750-eng.pdf. Accessed February 18, 2011.
24. Kasamba I, Baisley K, Mayanja BN, et al. The impact of antiretroviral treatment on mortality trends of HIV-positive adults in rural Uganda: a longitudinal population-based study, 1999-2009. Trop Med Int Health. 2012;17:e66-73.
25. Parkin DM, wabinga H, Nambooze S. Completeness in an African cancer registry. Cancer Causes Control. 2001;12:147-152.
26. Treat 3 Million by 2005 Initiative: ARV Treatment Guidelines and Technical and Operational Recommendations for ART. world Health Organization; 2003. Available at: http://whqlibdoc.who.int/hq/2003/ wHO-HIV-2003.18.pdf. Accessed December 20, 2010.
27. Doll R, Payne P, waterhouse J, eds. Cancer Incidence in Five Continents. 1st ed. Geneva, Switzerland: Union Internationale Contre le Cancer; 1966.
28. Segi M. Cancer Mortality for Selected Sites in 24 Countries (1950-57). Sendai, Japan: Department of Public Health, Tohoku University of Medicine; 1960.
29. Lahuerta M, Ue F, Hoffman S, et al. The problem of late ART initiation in sub-Saharan Africa: a transient aspect of scale-up or a long-term phenomenon. J Health Care Poor Underserved. 2013;24:359-383.
30. Shumba C, Atuhaire L, Imakit R, et al. Missed doses and missed appointments: adherence to ART among adult patients in Uganda. ISRN AIDS. 2013;2013:270914.
31. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med. 1999;131:81-87.
32. Meireles P, Albuquerque G, Vieira M, et al. Kaposi sarcoma incidence in Mozambique: national and regional estimates. Eur J Cancer Prev. 2014.
33. Musinguzi J, Kirungi w, Akol Z, et al. The HIV/AIDS Surveillance Report. Uganda Ministry Of Health; 2010. Available at: http://www. unaids.org/en/media/unaids/contentassets/documents/data-and-analysis/ tools/spectrum/Uganda2011report.pdf. Accessed October 30, 2013.
34. Bratcher LF, Sahasrabuddhe VV. Review the impact of antiretroviral therapy on HPV and cervical intraepithelial neoplasia: current evidence and directions for future research. Infectious Agents Cancer. 2010;5:8.
35. Mbulaiteye SM, Buonaguro FM. Infections and cancer: debate about using vaccines as a cancer control tool. Infect Agent Cancer. 2013;8:16.
36. Sayi A, Kohler E, Hitzler I, et al. The CD4+ T cell-mediated IFN-gamma response to helicobacter infection is essential for clearance and determines gastric cancer risk. J Immunol. 2009;182:7085-7101.